CD14+S100A9+ myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 10, 2012, Pages 940-941

  Sharma, Sherven ^a,b   Dubinett, Steven ^a,b   Salgia, Ravi ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CISPLATIN; GAMMA INTERFERON; PROTEIN S 100; PROTEIN S 100 A9; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CYTOKINE PRODUCTION; EDITORIAL; GENE EXPRESSION; LUNG CANCER; PRIORITY JOURNAL;

ANTIGENS, CD14; CALGRANULIN B; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNE TOLERANCE; LUNG NEOPLASMS; MALE; MYELOID CELLS;

EID: 84869228608     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201209-1597ED     Document Type: Editorial

References (5)

1. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR, Okada H. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011;71:2664-2674.
2. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Chaudhury AR, La Perle KM, et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 2011;71:5101-5110.
3. Srivastava MK, Zhu L, Harris-White M, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS 2012 7:e40677.
4. + monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med 2012;186:1025-1036.
5. Zhao F, Hoechst B, Duffy A, Gamrekelashvili J, Fioravanti S, Manns MP, Greten TF, Korangy F. S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology 2012;136:176-183.